Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class ...
This agreement, effective September 1, 2026 through August 31, 2028, establishes Zomedica as a preferred provider of advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results